CaDAnCe-101
Phase 1/2 Recruiting
614 enrolled
MAHOGANY
Phase 3 Recruiting
780 enrolled
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Phase 2 Recruiting
125 enrolled
CaDAnCe-302
Phase 3 Recruiting
250 enrolled
CaDAnCe-303
Phase 3 Recruiting
150 enrolled
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 3 Recruiting
500 enrolled
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Phase 3 Recruiting
500 enrolled
Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma
Phase 2 Recruiting
65 enrolled
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/2 Recruiting
263 enrolled 2 FDA
PRIMAVERA
Phase 1/2 Recruiting
161 enrolled
SOUNDTRACK-D2
Phase 3 Recruiting
420 enrolled
Study of Out of Specification for Tisagenlecleucel
Phase 3 Recruiting
200 enrolled
waveLINE-003
Phase 2/3 Recruiting
290 enrolled
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Phase 1 Recruiting
121 enrolled
BRUIN-CLL-314
Phase 3 Recruiting
662 enrolled
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Phase 1 Recruiting
85 enrolled
LIBERTY
Phase 3 Recruiting
104 enrolled
MK-2140-011
Phase 2 Recruiting
594 enrolled
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
Phase 1 Recruiting
224 enrolled
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Phase 1/2 Recruiting
146 enrolled
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Phase 1/2 Recruiting
200 enrolled
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Phase 1/2 Recruiting
270 enrolled
ASHA-1
Phase 1 Recruiting
40 enrolled
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Phase 3 Recruiting
1,018 enrolled
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 4 Recruiting
150 enrolled
ALICIA(BY)
Recruiting
50 enrolled
MK-3475-G21
Phase 1/2 Recruiting
20 enrolled
Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
Phase 1/2 Recruiting
165 enrolled
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Phase 1/2 Recruiting
152 enrolled
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Phase 1 Recruiting
453 enrolled
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Phase 1/2 Recruiting
70 enrolled
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Phase 1/2 Recruiting
281 enrolled
AQUALIS
Recruiting
120 enrolled
MK-2140-010
Phase 3 Recruiting
1,046 enrolled
NETTER-3
Phase 3 Recruiting
240 enrolled
inMMyCAR
Phase 1 Recruiting
40 enrolled
OPAL
Phase 1/2 Recruiting
144 enrolled
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Phase 1/2 Recruiting
80 enrolled
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
Phase 4 Recruiting
60 enrolled
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Phase 3 Recruiting
630 enrolled
cAMeLot-1
Phase 1/2 Recruiting
420 enrolled
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Phase 1 Recruiting
572 enrolled
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Phase 1/2 Recruiting
308 enrolled
SynKIR-310 for Relapsed/Refractory B-NHL
Phase 1 Recruiting
36 enrolled
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Phase 1 Recruiting
280 enrolled
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Phase 2 Recruiting
100 enrolled
Lythesia
Recruiting
30 enrolled
CAN3001
Phase 3 Recruiting
700 enrolled
MK-1026-003
Phase 2 Recruiting
490 enrolled
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Phase 2 Recruiting
496 enrolled